These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3677541)

  • 1. Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans.
    Ishizaki T; Horai Y; Kubota K; Minegishi A; Echizen H; Chiba K
    Clin Pharmacol Ther; 1987 Nov; 42(5):525-34. PubMed ID: 3677541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological effects of intravenous nicaïnoprol, a new antiarrhythmic agent, in 11 patients.
    Libersa CC; Caron JF; Kacet S; Dagano J; Vincent A; Dupuis B; Gayet JL; Lekieffre JP
    Eur Heart J; 1988 Mar; 9(3):271-8. PubMed ID: 3383868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and dynamics of sematilide.
    Shi J; Lasser T; Koziol T; Hinderling PH
    Ther Drug Monit; 1995 Oct; 17(5):437-44. PubMed ID: 8585104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics.
    Page RL; Wharton JM; Wilkinson WE; Friedman IM; Claypool WD; Karim A; Kowalski KG; McDonald SJ; Gardiner P; Pritchett EL
    Clin Pharmacol Ther; 1992 Apr; 51(4):371-8. PubMed ID: 1563207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-related antiarrhythmic effects of nicainoprol in patients with chronic ventricular arrhythmias--a double-blind, placebo-controlled, cross-over multicentre trial. Nicainoprol Study Group.
    Schneider W; Reifart N; Blaeser A; Ostrowski J; Kaltenbach M; Kober G
    Eur Heart J; 1991 Aug; 12(8):900-8. PubMed ID: 1915428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effect of a new class 1 antiarrhythmic drug, nicainoprol, on canine ventricular arrhythmias.
    Hashimoto K; Akiyama K; Mitsuhashi H
    Jpn J Pharmacol; 1989 Feb; 49(2):245-54. PubMed ID: 2733262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propafenone shows class Ic and class II antiarrhythmic effects.
    Stoschitzky K; Stoschitzky G; Lercher P; Brussee H; Lamprecht G; Lindner W
    Europace; 2016 Apr; 18(4):568-71. PubMed ID: 26056191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.
    Bastain W; Boyce MJ; Stafford LE; Morton PB; Clarke DA; Marlow HF
    Eur J Clin Pharmacol; 1988; 34(5):469-73. PubMed ID: 2904884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.
    Sorensen EV; Faergeman O; Day M; Bastain W
    Eur J Clin Pharmacol; 1988; 35(2):183-5. PubMed ID: 2903827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of oral dosage and pharmacokinetic analysis of flecainide in horses.
    Ohmura H; Hiraga A; Aida H; Takahashi T; Nukada T
    J Vet Med Sci; 2001 May; 63(5):511-4. PubMed ID: 11411495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.
    Le Coz F; Funck-Brentano C; Morell T; Ghadanfar MM; Jaillon P
    Clin Pharmacol Ther; 1995 May; 57(5):533-42. PubMed ID: 7768076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of sematilide in renal failure.
    Shi J; Ripley E; Gehr TW; Sica DA; Dandekar KA; Hinderling PH
    J Clin Pharmacol; 1996 Feb; 36(2):131-43. PubMed ID: 8852389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam.
    Troy SM; Cevallos WH; Conrad KA; Chiang ST; Latts JR
    J Clin Pharmacol; 1991 May; 31(5):433-9. PubMed ID: 2050828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and pharmacokinetics of oral pirmenol, a new antiarrhythmic drug.
    Garg DC; Jallad NS; Singh S; Ng KF; Weidler DJ
    J Clin Pharmacol; 1988 Sep; 28(9):812-7. PubMed ID: 2466056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of nicainoprol, a new antiarrhythmic agent, in human plasma and urine by high-performance liquid chromatography.
    Horai Y; Ishizaki T
    J Chromatogr; 1986 Nov; 383(1):103-10. PubMed ID: 3818828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.
    Trenk D; Wagner F; Sachs W; Jähnchen E
    Eur J Clin Pharmacol; 1989; 37(3):313-6. PubMed ID: 2612546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration.
    Lecocq B; Jaillon P; Lecocq V; Ferry A; Gardin ME; Jarreau C; Leroyer R; Pays M; Jarreau FX
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):445-50. PubMed ID: 2465445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of sotalol.
    Hanyok JJ
    Am J Cardiol; 1993 Aug; 72(4):19A-26A. PubMed ID: 8346722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
    Li G; Gong PL; Qiu J; Zeng FD; Klotz U
    Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.
    Ito S; Gow R; Verjee Z; Giesbrecht E; Dodo H; Freedom R; Tonn GR; Axelson JE; Zalzstein E; Rosenberg HC; Koren G
    J Clin Pharmacol; 1998 Jun; 38(6):496-501. PubMed ID: 9650538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.